Charles River Laboratories International Inc - Company Profile
Powered by 
All the sales intelligence you need on Charles River Laboratories International Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Charles River Laboratories International Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Charles River Laboratories International Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Charles River Laboratories International Inc (Charles River) is a contract research organization that acts as a non-clinical global drug development partner. The company provides a comprehensive range of products and services, including research models, genetically engineered models and services, research animal diagnostic services, cell solutions, safety pharmacology, bioanalysis, discovery services, pathology services, microbial solutions, biologics testing services, and CDMO services. Its therapy area includes cardiovascular and metabolic diseases, oncology, ophthalmology, rare disease, renal disorders, COVID-19, immunology, infectious disease, microbiome research, neuroscience, and respiratory disease. The company offers its products and services to pharmaceutical, biotechnology, academic institutions; agricultural, and industrial chemical companies; and government agencies through the brands Endosafe, Celsis and Accugenix among others, in North America, Europe, and Asia. Charles River is headquartered in Wilmington, Massachusetts, the US.
Headquarters
United States of America
Address
251 Ballardvale Street, Wilmington, Massachusetts, 01887
Website
www.criver.com
Telephone
1 781 2226000
No of Employees
18,300
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CRL (NYSE)
Revenue (2024)
$4.0B
-0.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-1501.7%
(2024 vs 2023)
Market Cap*
$11.1B
Net Profit Margin (2024)
XYZ
-1,536.0%
(2024 vs 2023)
* As of and is in US$
Charles River Laboratories International Inc premium industry data and analytics
Products and Services
| Services | Brands |
|---|---|
| - | - |
| Research Models | Celsis |
| Small Research Models | Endosafe |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In June, the company signed a partnership with Lilly TuneLab to allow AI/ML drug discovery models trained on decades of Lilly's proprietary research data. |
| 2026 | Contracts/Agreements | In May, the company signed a strategic, non-exclusive memorandum of understanding with MEDIPOST for GMP-compliant testing and broader commercial and marketing efforts. |
| 2026 | Divestiture | In May, the company sold the Contract Development and Manufacturing Organization (CDMO) and Cell Solutions businesses to GI Partners. |
Competitor Comparison
| Key Parameters | Charles River Laboratories International Inc | WuXi Biologics Cayman Inc | Fortrea Holdings Inc | Almac Group Ltd | The Jackson Laboratory |
|---|---|---|---|---|---|
| Headquarters | United States of America | China | United States of America | United Kingdom | United States of America |
| City | Wilmington | Wuxi | Durham | Craigavon | Bar Harbor |
| State/Province | Massachusetts | Jiangsu | North Carolina | Northern Ireland | Maine |
| No. of Employees | 18,300 | 13,252 | 14,000 | 7,800 | 3,000 |
| Entity Type | Public | Public | Public | Private | Institution |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Birgit Girshick | Chief Executive Officer; Director | Executive Board | 2026 | 56 |
| Glenn Coleman | Chief Financial Officer; Corporate Executive Vice President | Senior Management | 2026 | - |
| Michael G. Knell | Chief Accounting Officer; Interim Chief Financial Officer; Corporate Senior Vice President | Senior Management | 2025 | - |
| Mark Mintz | Chief Information Officer; Corporate Executive Vice President-Global Shared Services Management | Senior Management | 2025 | 52 |
| Victoria L. Creamer | Chief People Officer; Corporate Executive Vice President | Senior Management | 2020 | 56 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer